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OBJECTIVES: Mastitis is one of the most frequent and costly diseases in the dairy
industry with gram-negative bacteria being the main causal agent. Since most
antibiotics have minimal effect on shortening the duration of clinical mastitis
caused by gram-negative pathogens (gram-CM) and because of a high spontaneous
cure rate, antibiotics are often not recommended for treating Gram-CM. The pur-
pose of this study was to develop a model comparing 5-day treatment with ceftio-
fur hydrochloride to no treatment of gram-CM, also allowing easy adaptations to
reflect the high variability of prices and cost data in livestock. METHODS: A deci-
sion tree was developed in MS Excel considering first and recurrent CM episodes,
culling and death of cows with gram-CM. Cure rates and other clinical data were
derived from published studies. Costs and losses associated with CM and its treat-
ment, culled or dead cows as well as income generated from saleable milk produc-
tion or sold cows were considered. Cost and income values were derived from
public sources (US-2010, perspective of the producer). All input parameters were
varied extensively in one-way sensitivity analyses. RESULTS: With US-2010 cost/
prices, income from saleable milk was $3,039.35 (ceftiofur) and $3069.67 (no treat-
ment), and costs associated with the disease and treatment totaled to $215.12
(ceftiofur) and $246.60 (no treatment) over the entire lactation period, resulting in a
$1.16 higher margin per treated cow with a 5-day treatment with ceftiofur com-
pared to no treatment of gram-CM.More cowswere cured and fewer cows culled or
died with ceftiofur. The model was most sensitive to ceftiofur cure rate and self-
cure rate. CONCLUSIONS: Compared to no treatment, ceftiofur’s higher treatment
costs and less income due to milk discard were offset by a better efficacy, resulting
in less disease associated costs of gram-CM.
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OBJECTIVES: Data documenting the incremental economic and health burden of
HCV infections will be required to evaluate the comparative effectiveness of new,
emerging HCV therapies. Our objective is to estimate the incremental cost associ-
atedwith hepatitis C infections [HCV] in real-world clinical practice.METHODS: Six
years of de-identified data from a U.S. health insurer [2003-2008] were used to
identify patients with HCV with at least two years of data prior to and following
their first HCV diagnosis or the start of antiviral drug therapy [index date]. Non-
HCV patients with 2 years of eligibility were identified and patients with a pre-
index diagnosis for HIV, hepatitis B, cirrhosis, liver cancer or a liver transplantation
were excluded. Propensity score matching was used to match the patients with
HCV to similar non-HCV patients on a 1-to-1 ratio. The incremental impact of HCV
on post-index cost and adverse event risk were estimated controlling for patient
demographics, diagnostic profile, and prescription drug profile. RESULTS: The
8,861 HCV patients and 8,861matched non-HCV patients in the study sample were
60%male, age 50 years old. Post-index total cost of HCV andnon-HCVpatientswere
$37,390 and $13,575, respectively, in the first year. The incremental cost of HCVwas
estimated at$23,406 due primarily to higher costs for ambulatory care [$6,531],
hospital services [$1,827] and prescription drugs [$6,935]. HCV was associated
with higher risk of hospitalization [Odd Ratios (O.R.) 2.5]; depression [O.R.. 2.2];
cirrhosis [O.R. 65.8]; hepatic cancer [O.R. 28.1] and liver transplantation [O.R.
46.1] [p0.0001 for all estimates]. CONCLUSIONS: Newly diagnosed HCV patients
experience significantly higher cost and adverse event risk relative to matched
non-HCV patients. These results highlight the need for safe, tolerable and effective
antiviral therapies, and the need for risk predicting tools to identify HCVpatients at
high risk for adverse events.
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OBJECTIVES: Severe sepsis (SS) contributes to a high economic burden among
critically ill patients. The objective of the study was to describe SS population and
determine associated costs.METHODS: Data was drawn from a large IHS (Jan 2002
to Dec 2008) and included two groups of adult patients; SSD: SS or septic shock
ICD-9 code (995.92 and 785.52); and NSSD: SS criteria by Angus (2001) and Martin
(2003). Patients were evaluated at index hospitalization, 30-days (30D), 30-days-6-
months (30D-6M), and 6-months-1year (6M-1YR) post-discharge. Comorbidities,
antibiotic use, supportive treatment, mortality, and costs were analyzed. Costs
were adjusted to 2009 US Dollars using the overall urban CPI; 0.65 (cost-to-charge-
ratio) was applied to charge data. Follow-up cost analysis was limited to patients
with complete data at the beginning of each evaluation period. RESULTS: The
cohort included 17,256 patients: 3,229 (19%) SSD and 14,027 (81%) NSSD. The groups
had similar baseline demographics and comorbidities. SSD had a higher rate of ICU
admission (81% vs. 47%). Nearly all received antibiotics. Supportive treatments
included vasopressors (66% vs. 19%) and mechanical ventilation (71% vs. 39%).
Mean length of stay (LOS) was 212d for SSD and 1414d for NSSD. Hospital mor-
tality was 40% for SSD and 11% for NSSD; overall mortality at 1-year pdschg was
61% and 39%, respectively. Mean cost of hospitalization was $75K107K, with
SSD costing almost double NSSD ($123K149K vs. $64K$91K). In all three fol-
low-up periods, NSSD incurred higher costs ($18K34K vs. $14K27K for 30D,
$54K102K vs. $42K81K for 30D-6M, and $34K67K vs. $27K56K for 6M-1YR.
CONCLUSIONS: SSD patients have higher rates of mortality, both during hospital-
ization and in the year following, compared to NSSD patients. The higher mean
hospitalization costs for SSD may be due to longer LOS/ more intensive resource
use. The lower overall 1-yearmortality rate in NSSDmay be associated with higher
follow-up costs.
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OBJECTIVES: The treatment of surgical site infections (SSI) is associated with high
costs for the statutory health insurance (SHI) and for hospitals. The DRG-reim-
bursement for septic revisions seems to be not cost-covering for hospitals.Without
an Arthroplasty Register for Germany, exact numbers for SSI in hip arthroplasty
and knee arthroplasty are not available. Also there is no approximation for the
financial impact, yet. The purpose of this work is to estimate the financial impact
and possible risk of SSI in knee and hip arthroplasty for SHI and hospitals.
METHODS: To estimate the number of SSI for Germany, a projection for all SSI in
primary hip and knee replacements in Germany (N372.851) was made with data
from the KISS module surgical (“Krankenhaus-Infektions-Surveillance-System”).
Two approaches were used to assess the costs: First, treatment expenses from the
Barmer GEK-report were used and second a bottom-up analysis based on themed-
ical and pharmaceutical costs of the treatment algorithm for SSI. RESULTS: The
revision treatment of SSI resulted in a financial burden of at least € 22.407.350 for
hip replacement and € 13.760.280 for knee replacement for the SHI. Due to the even
higher medical and pharmaceutical costs for the treatment of SSI in hospitals, SSI
can cause a financial loss to them. CONCLUSIONS: To achieve a cost-covering
treatment of SSI in hospitals, the severalmethods of reducing the risk of SSI should
be checked with a cost-minimization-analysis. Then, hospitals have the opportu-
nity to calculate the risk of higher SSI-rates against higher costs for primary re-
placement with a reduced risk of SSI. For the SHI a cost-benefit-analysis could be
helpful to make a decision about requirements on methods used in primary re-
placement in hospitals to reduce the rate off SSI. A German Arthroplasty Register
should include the collection of SSI data in its dataset.
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OBJECTIVES: In Canada, nosocomial pneumonia (NP) and complicated skin and
soft tissue infection (CSSTI) caused by MRSA are often treated with antibiotics
administered in hospital, with a follow-up course administered at home for stable
patients. Typically, IV vancomycin is used when MRSA is the proven or suspected
pathogen. Our objective was to evaluate the potential treatment cost impact using
oral (PO) linezolid vs. IV vancomycin for NP and CSSTI therapy, using a Net Impact
Analysis approach for Quebec.METHODS: Data on healthcare resource utilization
associated with linezolid and vancomycin therapy were collected for patients with
NP or CSSTI in Quebec. Costs were assigned to healthcare resources (antibiotics,
medical supplies, laboratory testing and healthcare professionals’ time) based on
unit prices. Based on expert opinion, analyses assumed IV vancomycin is admin-
istered in hospital for an average of 10 or 5 days followed by 11 or 9 days at home for
NP or CSSTI, respectively, whereas linezolid is administered in hospital for 5 or 2
days IV then 5 or 3 days PO, followed by 11 or 9 days PO at home for NP or CSSTI,
respectively. RESULTS: Antibiotic acquisition costs were higher for linezolid than
for vancomycin, both in hospital (Can$1,696.20 vs. $186.00 and $822.72 vs. $93.00
for NP and CSSTI, respectively) and for home therapy ($1,655.30 vs. $1,531.05 and
$1,355.87 vs. $1,242.08 for NP and CSSTI, respectively). However, total treatment
costs including costs for preparing, administering andmonitoring drug levels were
lower for linezolid vs. vancomycin, thus offsetting drug acquisition costs (total
treatment costs: $6,582.62 vs. $7,599.00 and $3,849.80 vs. $5,141.02 for NP and
CSSTI, respectively). CONCLUSIONS: In this net impact study, using linezolid com-
pared to vancomycin to treat NP and CSSTI, for hospital and home courses com-
bined, reduces healthcare resource utilization and costs.
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TREATMENT PATTERNS AND DRUG TREATMENT COSTS ASSOCIATED WITH
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OBJECTIVES: Guidelines recommend that patients with HIV infection who are
naïve to treatment receive two nucleoside reverse transcriptase inhibitors (NRTI)
plus a third agent which may be a non nucleoside reverse transcriptase inhibitor
(NNRTI), protease inhibitor (PI), or integrase inhibitor (II). This study examined
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treatment patterns and drug treatment costs in such patients. METHODS: Retro-
spective analysis of pooled US health insurance claims data for commercially in-
sured (Pharmetrics/I3/Thomson) and Thomson Medicaid patients, 2007–2009.
RESULTS:Data from 14,002 treatment-naïve patientswere collected. 6,801 patients
(49%) started on an NNRTI (of which 99.8% on efavirenz, mainly as part of a fixed-
dose combination), 5,966 (43%) on a PI and 1,235 (9%) on an II or another third agent.
As expected due to the teratogenic potential of efavirenz, substantially fewer
women aged40 years started NNRTI treatment (32.5% vs 60% starting a PI). Of all
patients who started on efavirenz, 66% remained on this initial treatment at 1 year.
Of patients who switched to another regimen after discontinuing efavirenz, 85%
changed to a PI-based regimen. At the start of efavirenz treatment,mean daily drug
cost (including 2 NRTIs) was 46 USD. For patients who switched subsequently to a
PI-based regimen, mean daily drug cost rose by 51% to 70 USD. Corresponding
values from the individual databases were consistent. CONCLUSIONS:Within one
year after initiation of therapy,many patients discontinue efavirenz.When chang-
ing to another regimen, themajority switch to a PI, with an associated rise in costs.
The study highlights opportunities in the current HIV treatment-naïvemarket and
the need for new third agents which are as effective but better tolerated than
efavirenz, and may be used in women of childbearing potential. Such agents may
alleviate the need to start with and/or delay the switch to more expensive treat-
ments, potentially reducing HIV treatment costs.
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OBJECTIVES: Vaccinating birth mothers with influenza vaccine in the immediate
postpartum period can protect both the vaccine recipients and their young infants
who are ineligible for any influenza vaccine. The study objective was to estimate
the potential economic benefit associated with this intervention. METHODS: A
decision analysis model was constructed to determine the probabilities, costs and
potential cost-benefit of a postpartum influenza vaccination strategy using a soci-
etal perspective. A hypothetical cohort of 4 million healthy birth mothers in the
United States was included into a decision tree model assuming an influenza sea-
son beginning September 1 and ending April 30. Probabilities and costs used in this
study were derived from our review of published literature, unpublished data re-
ported from Centers for Disease Control and Prevention (CDC), and recent pub-
lished clinical trial data. All direct and indirect cost estimates were inflated to year
2010 US dollars and discounted at a 3% annual discount rate. RESULTS: Under the
base-case assumptions, the average costs per vaccinated mother and per unvacci-
nated mother were estimated at $328.45 and $341.02, respectively. Our model sug-
gests an expectednet societal benefit of $12.57 per post-partumvaccinatedmother,
compared to no vaccination. The overall societal savings in this cohort ranged from
$20,112,186 to $45,252,420, depending on the vaccination coverage rate. Annual
attack rate in birth mothers and influenza vaccine efficacy also exhibited substan-
tial impact on the model from one-way and two-way sensitivity analyses.
CONCLUSIONS: Widespread adherence to a postpartum influenza vaccine usage
strategy is likely to show positive net societal benefits in the United States, if the
annual attack rate among birth mothers exceeds 2.8%, if the influenza vaccine
efficacy reaches 47%, or if vaccine acquisition and administration cost per dose is
less than $32.78.
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OBJECTIVES: Estimating the financial benefit or cost of using anti-retroviral med-
ications (ARVs) for treating HIV in Uganda in light of poor concordance, risk of
treatment resistant strains developing, patients living longer and the potentially
increased risk of spreading the virus. METHODS: We performed a cost-benefit
study to analyze the effects, in monetary terms, of ARVs in Uganda, from the
societal perspective. Data were obtained from administering institutions such as
the ministry of health, identified non-governmental organizations such as The
Aids Support Organization (TASO), Mildmay International, and research centers
plus published literature. Human capital approach was used to estimate costs.
Monetary estimateswere available in Uganda shillings and their dollar equivalents
were computed. The study included programs specifically funded by donor funds
and/or the Ugandan government. RESULTS: The estimated net benefit from ARVs
for a year was estimated at $8,250 per patient. Benefits were in the form of im-
proved productivity resulting from prolonged life overall with minimal counter-
effects of developing treatment resistant strains and increased risk of spreading
the virus. One-way sensitivity analysis showed the net benefit to vary from $1,656
to $13,871. CONCLUSIONS: Using ARVs to treat HIV in Uganda is cost beneficial for
the Ugandan society.
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OBJECTIVES: Pneumococcus was responsible formore than 50% of the preventable
deaths in infants under 5 years of age according to the Pan American Health Orga-
nization before the introduction of conjugate vaccines. The objective of this anal-
ysis is to evaluate the cost effectiveness of vaccinating the Colombian population
younger than 2 years of age with 13-valent vaccine (PCV 13) in comparison to the
10-valent or PHiD-CV vaccine (PCV 10) both in same schedule.METHODS: In order
to estimate the costs and the impact of the pneumococcal disease, aMarkovmodel
simulating vaccination and outcomes of 10 annual birth cohortswas adapted to the
Colombian conditions from the Health System perspective. The probabilities and
the costs were extracted from a literature review and tariff manuals applicable for
Colombia for January 2011, with costs presented in US$. The results in health are
expressed as number of cases of diseases and deaths prevented, as well as in terms
of life years (LYs) and QALYs saved. Probabilistic sensitivity analyses were done.
RESULTS: Over a 10 year period, vaccinating with PCV13 prevents 8,191 cases of
invasive pneumococcal disease, 58,587 hospitalized pneumonia, 5,583 non com-
plicated pneumonia and 2,927 deaths, saving 70,640 LY’s and 63,697 QALY’s
compared to PCV10. PCV10 prevents 49,354 additional cases of acute otitis me-
dia versus PCV13. The total costs including vaccination costs and medical costs
are US$ 89,608,061 less for PCV13 compared to PCV10 (US$ 2,365,043,131 vs. US$
2,454,651,191). The model shows robustness in the sensibility analysis.
CONCLUSIONS: The analysis suggests that vaccinating infants with PCV13 in Co-
lombia is a cost-saving alternative in comparison with PHiD-CV. The results in
economic and disease burden are substantial and they support the decision mak-
ing in favor of PCV13 for its high impact in public health.
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OBJECTIVES: Hepatitis B virus (HBV) causes 0.2% of world deaths, especially in
developing countries. This does not include deaths of hepatocellular carcinoma
(HCC), and hepatic cirrhosis (HC) caused by HBV. To diminish the burden of HBV
chronic and acute infection, in an unvaccinated cohort, we proposed a cost-effec-
tiveness analysis to assess the impact of the introduction of HBV vaccine in Co-
lombian adolescents.METHODS: A Markov model was made for two cohorts (vac-
cinated and unvaccinated) of people between 15 and 20 years old, who were be
followed for 30 years. Vaccination was assumed 97% effective in a three dose
scheme, and coverage of 70%. Costs were obtained from a database of Colombian
private health insurers. A model to estimate natural history of HBV infection was
used, along with data from literature reviews. All costs were 2009 US dollars. Vac-
cine administration cost plus vaccine price were assumed as US$7. A 3% discount
rate was applied to cost and outcomes. A sensitivity analysis was made to assess
the uncertainty in the assumptions.RESULTS:Deaths fromHBV infectionwould be
709 in the cohort without vaccination, and 228 in the cohort with vaccination.
Life-years gained (LYG) from vaccination with 70% coverage would be 12,266. Total
cost in not vaccinated is US$27,840,220; in vaccinated is US$8,936,710. Incremental-
Cost-Effectiveness Ratio (ICER) per LYG would be 665 US$/LYG. ICER per avoided
death would be 16,957 US$/avoided death. CONCLUSIONS: HBV vaccine is highly
cost-effective according toWorld Health Organization criteria (less than per-capita
gross domestic product). This is the first study that assessed the adolescent vacci-
nation with HBV in Latin America. The investigators strongly recommend the im-
plementation of this intervention to impact the burden of disease HBV-associated
in Colombia.
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OBJECTIVES: In the last years in Mexico HIV/AIDS appears within the first seven
causes of mortality among the population between 15 and 64 years old (SINAIS).
Boosted PI combination therapy, in combination with other advances, has lowered
the mortality rate among HIV-infected patients almost to that of the uninfected
population. The 96-week CASTLE randomized trial demonstrated that, in HAART-
naïve patients, ATV/RTV was non-inferior to LPV/RTV for suppressing viral repli-
cation and caused lower rates of GI toxicity and lower increases in total cholesterol.
In this study we evaluated the cost-effectiveness of ATV/RTV versus LPV/RTV in
treatment-naïve HIV patients in Mexico, using results from the CASTLE study.
METHODS: A lifetime Markov micro simulation model was used to estimate the
cost per QALY for both therapies lifetime costs, clinical outcomes and cost-effec-
tiveness. Tenofovir-emtricitabinewas considered the backbone therapy. Amillion-
member cohort of HIV-infected, treatment-naïve adults progressed at 3-month
intervals through 8 health states. The model measures the cost per adverse event
averted of the ATV based regime, focusing in particular on GI and coronary heart
disease outcomes. The analysis was conducted from the Mexican Health care per-
spective. Outcomes were discounted at a 5% rate. Virologic suppression, health
state transition probabilities, cholesterol changes, and side effect rates were de-
rived from CASTLE. Costs and utilities were derived from literature and expert
opinion. RESULTS: Patients initiating ATVRTV regime had longer quality-ad-
justed survival than those initiating LPVRTV, (10.47 vs. 10.26 years) and lower
total costs ($95,579 vs. $103,891 USD) resulting in a more effective and less costly
treatment option (dominant alternative). Sensitivity analyses demonstrated that
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